TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31289064

Group type: EXPERIMENTAL
Intervention: E+PBP (national e-learning programme plus PBP simulation)
Number of subjects: 90

Group type: COMPARATOR
Intervention: E (national NEWS e-learning programme only)
Number of subjects: 90

Group type: COMPARATOR
Intervention: E+S (national e-learning programme plus standard simulation)
Number of subjects: 90
Study: 27555097

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 38

Group type: COMPARATOR
Intervention: Multidisciplinary, group-based medical diabetes and weight management program
Number of subjects: 38
Study: 26004393

Group type: EXPERIMENTAL
Intervention: S-1 administration for more than 1 year
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: S-1 administration periods of 24 months or longer
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: S-1 administration
Number of subjects: 89
Study: 23452670

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Volumetric arc therapy (VMAT)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Tomotherapy (TOMO)
Number of subjects: 5

Group type: COMPARATOR
Intervention: VMAT (normalized by IMRT)
Number of subjects: 5

Group type: COMPARATOR
Intervention: TOMO (normalized by IMRT)
Number of subjects: 5
Study: 21252828

Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy (LDN)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Open donor nephrectomy (ODN)
Number of subjects: 84
Study: 19307517

Group type: EXPERIMENTAL
Intervention: Oral vitamin D (with or without calcium)
Number of subjects: 42279

Group type: EXPERIMENTAL
Intervention: Higher dose of oral vitamin D (>400 IU/d)
Number of subjects: 42279
Study: 16870768

Group type: EXPERIMENTAL
Intervention: Tefibazumab (20 mg/kg as a single infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 14997746

Group type: EXPERIMENTAL
Intervention: Breast conservation treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Breast conservation treatment in ductal carcinoma in situ
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient selection for breast conservation without radiation
Number of subjects: 0
Study: 11607948

Group type: EXPERIMENTAL
Intervention: Aromatherapy and massage (AM)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conversation and aromatherapy (CA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Massage only (M)
Number of subjects: 21
Study: 9476185

Group type: EXPERIMENTAL
Intervention: Ranitidine, prescribed to 73.9% of patients receiving treatment.
Number of subjects: 3685

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment motivated by fear of stress mucosal lesions (28%) and therapy with other drugs (56%).
Number of subjects: 3685

Group type: EXPERIMENTAL
Intervention: General prescription practices for peptic diseases.
Number of subjects: 3685
Study: 7705196

Group type: EXPERIMENTAL
Intervention: Healthy subjects
Number of subjects: 17

Group type: COMPARATOR
Intervention: Obese patients
Number of subjects: 17
Study: 2959623

Group type: EXPERIMENTAL
Intervention: GTF vaccine with aluminum phosphate (AP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sodium phosphate buffer with aluminum phosphate (AP) (Control)
Number of subjects: 25
Study: 28097476

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) for 12 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) groups
Number of subjects: 23
Study: 26995403

Group type: EXPERIMENTAL
Intervention: Coronary CT Angiography
Number of subjects: 10003

Group type: COMPARATOR
Intervention: Functional Testing
Number of subjects: 10003
Study: 24731231

Group type: EXPERIMENTAL
Intervention: Exogenous glutamine supplementation (L-alanyl-L-glutamine, 0.28 g/kg during 20 hours)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Basal measurements without supplementation
Number of subjects: 11
Study: 23529377

Group type: EXPERIMENTAL
Intervention: Prescriptive message tone
Number of subjects: 1865

Group type: EXPERIMENTAL
Intervention: Dictated navigation autonomy
Number of subjects: 1865

Group type: EXPERIMENTAL
Intervention: Proactive email reminders
Number of subjects: 1865

Group type: EXPERIMENTAL
Intervention: Tailored testimonials
Number of subjects: 1865
Study: 19703825

Group type: EXPERIMENTAL
Intervention: Targeted treatment
Number of subjects: 177

Group type: COMPARATOR
Intervention: Empirical treatment
Number of subjects: 177
Study: 18940387

Group type: EXPERIMENTAL
Intervention: Peroral estradiol valerate
Number of subjects: 73

Group type: COMPARATOR
Intervention: Transdermal 17beta‐estradiol gel
Number of subjects: 73
Study: 12090410

Group type: EXPERIMENTAL
Intervention: 3-wave intensive design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pretest as a covariate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard analysis of covariance on the posttest with the pretest as covariate
Number of subjects: 0
Study: 9647367

Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 196
Study: 7734015

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 354
Study: 2481772

Group type: EXPERIMENTAL
Intervention: Nicardipine (NIC) 20 mg t.i.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Captopril (CAP) 50 mg b.i.d.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nicardipine plus Captopril (NIC + CAP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 12
Study: 236075

Group type: EXPERIMENTAL
Intervention: Light anaesthesia with ketamine/diazepam
Number of subjects: 4

Group type: COMPARATOR
Intervention: Light halothane anaesthesia
Number of subjects: 4
Study: 31419298

Group type: EXPERIMENTAL
Intervention: WHO grade III versus IV
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: H3F3A K27M mutation
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Midline location
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: High Ki-67 index (≥20%)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Ki-67 index increase
Number of subjects: 118
Study: 30773441

Group type: EXPERIMENTAL
Intervention: 155° prosthesis
Number of subjects: 100

Group type: COMPARATOR
Intervention: 135° prosthesis
Number of subjects: 100
Study: 28947724

Group type: EXPERIMENTAL
Intervention: Low dose rivaroxaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 26086281

Group type: EXPERIMENTAL
Intervention: Deep anaesthesia in lateral position
Number of subjects: 216

Group type: COMPARATOR
Intervention: Deep anaesthesia in supine position
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Awake in lateral position
Number of subjects: 216

Group type: COMPARATOR
Intervention: Awake in supine position
Number of subjects: 216
Study: 23098686

Group type: EXPERIMENTAL
Intervention: AZD9164 100 μg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AZD9164 400 μg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AZD9164 1200 μg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Tiotropium 18 μg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 21421502

Group type: EXPERIMENTAL
Intervention: Urokinase and argatroban administered regionally via small saphenous vein catheter
Number of subjects: 56

Group type: COMPARATOR
Intervention: Urokinase and argatroban administered via peripheral vein (control)
Number of subjects: 56
Study: 20195007

Group type: EXPERIMENTAL
Intervention: Psychoeducational prevention program (PEP)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Psychiatrist-enhanced PEP
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: CBT-enhanced PEP
Number of subjects: 267

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 267
Study: 16893433

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg t.i.d. for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 15330957

Group type: EXPERIMENTAL
Intervention: Thoracic epidural morphine 0.1 mg x kg(‐1) in 0.2 ml x kg(‐1) saline (TEP group, n = 16)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Morphine infusion at 0.02 mg x kg(‐1) h(‐1) (INF group, n = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both TEP and INF groups
Number of subjects: 32
Study: 11252116

Group type: EXPERIMENTAL
Intervention: Rapid D-dimer assay
Number of subjects: 470

Group type: COMPARATOR
Intervention: Control (no rapid D-dimer assay)
Number of subjects: 470
Study: 9009045

Group type: EXPERIMENTAL
Intervention: Exposure with response prevention (standard behavior therapy protocol including in vivo and imagery exposure)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Maintenance program (for 5 patients)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (5 patients not in maintenance program)
Number of subjects: 10
Study: 8390952

Group type: EXPERIMENTAL
Intervention: High dose interferon alfa‐2b (6 million units)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dose interferon alfa‐2b (3 million units)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of plasma hepatitis C virus‐RNA
Number of subjects: 0
Study: 30934001

Group type: EXPERIMENTAL
Intervention: Low stability RT (Smith machine)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Medium stability RT (Free-weight)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: High stability RT (Wobble board)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: All training groups
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Familiarization period
Number of subjects: 59
Study: 29165697

Group type: EXPERIMENTAL
Intervention: Lift-less intervention (reducing lifting and carrying)
Number of subjects: 7
Study: 26100254

Group type: EXPERIMENTAL
Intervention: Tourniquet-assisted knee arthroplasty
Number of subjects: 28

Group type: COMPARATOR
Intervention: No tourniquet
Number of subjects: 28
Study: 24685847

Group type: EXPERIMENTAL
Intervention: Methotrexate 15 mg weekly for 12 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (calcium carbonate) for 12 weeks
Number of subjects: 29
Study: 22142891

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (LcS) intake for 3 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo intake for 3 weeks
Number of subjects: 72
Study: 20431021

Group type: EXPERIMENTAL
Intervention: H‐AE group (hypoxic‐absolute exercise, 50% maximum work rate under 15% O(2))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: H‐RE group (hypoxic‐relative exercise, 50% maximal heart rate reserve under 15% O(2))
Number of subjects: 60

Group type: COMPARATOR
Intervention: N‐E group (normoxic exercise, 50% maximum work rate under 21% O(2))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hypoxic (15% O(2)) resting control
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normoxic (21% O(2)) resting control
Number of subjects: 60
Study: 18155500

Group type: EXPERIMENTAL
Intervention: Ultrasonics + EDTA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Phosphoric acid
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: EDTA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ultrasonics
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MTwo‐PF drill
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Largo drill
Number of subjects: 100
Study: 16160709

Group type: EXPERIMENTAL
Intervention: Methylphenidate (40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14987202

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 49
Study: 15016224

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 35

Group type: COMPARATOR
Intervention: Regular insulin
Number of subjects: 35
Study: 8958191

Group type: EXPERIMENTAL
Intervention: Cilazapril (1 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 19
Study: 1286486

Group type: EXPERIMENTAL
Intervention: Etodolac 600 mg/day
Number of subjects: 172

Group type: COMPARATOR
Intervention: Diclofenac 150 mg/day
Number of subjects: 172
Study: 3927650

Group type: EXPERIMENTAL
Intervention: 5 mg L-Deprenyl per day
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: L-Deprenyl
Number of subjects: 19
Study: 29688628

Group type: EXPERIMENTAL
Intervention: Verinurad 10 mg + Febuxostat 40 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Verinurad 2.5 mg + Febuxostat 80 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Verinurad 10 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Febuxostat 40 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Verinurad 2.5 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Febuxostat 80 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Verinurad
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Verinurad and Febuxostat combination
Number of subjects: 23
Study: 29314344

Group type: EXPERIMENTAL
Intervention: Intensive fluoride varnish treatment (three applications within 2 weeks and additional applications at 1 and 3 months)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of care (semi-annual fluoride varnish treatment)
Number of subjects: 80
Study: 27152633

Group type: EXPERIMENTAL
Intervention: TORS training curriculum with ex vivo dissection models
Number of subjects: 0
Study: 25052229

Group type: EXPERIMENTAL
Intervention: Single-strain probiotic (Bifidobacterium animalis subsp. lactis Bl-04)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double-strain probiotic (Lactobacillus acidophilus NCFM and Bifidobacterium animalis subsp. lactis Bi-07)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22613001

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 19551536

Group type: EXPERIMENTAL
Intervention: Minocycline trial participants
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: NIV (Non-Invasive Ventilation)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: PEG (Percutaneous Endoscopic Gastrostomy)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Quality of Life decline
Number of subjects: 412
Study: 17935245

Group type: EXPERIMENTAL
Intervention: DALI (Fresenius)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Liposorber D (Kaneka)
Number of subjects: 6
Study: 15695478

Group type: EXPERIMENTAL
Intervention: Kundalini Yoga (KY) protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation Response and Mindfulness Meditation (RRMM) techniques
Number of subjects: 0
Study: 11859046

Group type: EXPERIMENTAL
Intervention: Ultrasonography and abdominal radiography
Number of subjects: 114

Group type: COMPARATOR
Intervention: Intravenous urography
Number of subjects: 114
Study: 10102764

Group type: EXPERIMENTAL
Intervention: Citicoline (500 mg bid)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7778430

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol for 12 weeks
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 223
Study: 2112022

Group type: EXPERIMENTAL
Intervention: Screening programme carried out by nurses (home visit, 45 minutes assessment)
Number of subjects: 296
Study: 475542

Group type: EXPERIMENTAL
Intervention: Home Care
Number of subjects: 155

Group type: COMPARATOR
Intervention: Hospital Care
Number of subjects: 155
Study: 31918682

Group type: EXPERIMENTAL
Intervention: Behavioral design methodology to improve respectful maternity care
Number of subjects: 0
Study: 30671586

Group type: EXPERIMENTAL
Intervention: Contralaterally controlled functional electrical stimulation (CCFES)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional neuromuscular electrical stimulation (NMES)
Number of subjects: 41
Study: 27681481

Group type: EXPERIMENTAL
Intervention: Occupation-based intervention
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Rote exercise intervention
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (different activities with affected hand)
Number of subjects: 36
Study: 26010687

Group type: EXPERIMENTAL
Intervention: Talactoferrin (1.5g, 15mL) three times a day orally or by another enteral route for 28 days
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Talactoferrin (1.5g, 15mL)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 23395772

Group type: EXPERIMENTAL
Intervention: MHADRO (intervention)
Number of subjects: 836

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 836
Study: 21330636

Group type: EXPERIMENTAL
Intervention: GLP-1 (1.2 pmol · kg⁻¹ · min⁻¹)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GIP (4 pmol · kg⁻¹ · min⁻¹)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GLP-1 plus GIP
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18637139

Group type: EXPERIMENTAL
Intervention: CDM-based VAS decision tool
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: CDM-based TTO decision tool
Number of subjects: 138
Study: 17459479

Group type: EXPERIMENTAL
Intervention: 4 mg of intravitreal triamcinolone (TA)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 4 mg of intravitreal triamcinolone (TA) combined with sequential grid laser
Number of subjects: 111

Group type: COMPARATOR
Intervention: Grid laser photocoagulation
Number of subjects: 111
Study: 14717388

Group type: EXPERIMENTAL
Intervention: Beta-blockers in addition to digoxin, diuretics, and ACE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study: 11115031

Group type: EXPERIMENTAL
Intervention: Early home-based intervention with weekly home visits from a child health nurse for 6 weeks, then fortnightly visits to 3 months, with some receiving short-term dynamic therapy from a social worker.
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 181
Study: 9190006

Group type: EXPERIMENTAL
Intervention: Floctafenin, 800 mg/day
Number of subjects: 192

Group type: COMPARATOR
Intervention: Acetaminophen, 3000 mg/day
Number of subjects: 192
Study: 1541877

Group type: EXPERIMENTAL
Intervention: Warfarin as an adjuvant to standard treatment
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Warfarin enantiomers (R,S) analysis
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Warfarin disposition
Number of subjects: 196
Study: 3020703

Group type: EXPERIMENTAL
Intervention: Etoposide with CAV (cyclophosphamide, doxorubicin, vincristine)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Prophylactic cranial irradiation
Number of subjects: 528

Group type: COMPARATOR
Intervention: Immunotherapy
Number of subjects: 528

Group type: COMPARATOR
Intervention: Sequential hemibody radiotherapy
Number of subjects: 528
Study: 31322496

Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cells (PBMC) transfer; 0.4 ml of cultured PBMCs transferred into the uterus two days prior to embryo transfer
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (no PBMC transfer)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cells (PBMC) transfer; limited analysis to patients with ≥3 RIFs
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (no PBMC transfer); limited analysis to patients with ≥3 RIFs
Number of subjects: 250
Study: 31229622

Group type: EXPERIMENTAL
Intervention: GEM intervention (tablet-delivered goal setting tool, health coaching visit, twelve telephone calls, provider counseling training)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GEM intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) (health education materials)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 19
Study: 28464026

Group type: EXPERIMENTAL
Intervention: Recombinant Na-GST-1 (10, 30, or 100 μg) adjuvanted with Alhydrogel
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Recombinant Na-GST-1/Alhydrogel with GLA-AF
Number of subjects: 142

Group type: COMPARATOR
Intervention: Hepatitis B vaccine
Number of subjects: 142
Study: 24998403

Group type: EXPERIMENTAL
Intervention: High-frequency transcutaneous peripheral nerve stimulation (HF-TPNS)
Number of subjects: 10
Study: 24322191

Group type: EXPERIMENTAL
Intervention: Fresh cheese enriched with Bifidobacterium lactis Bi‐07 (30 g/day for 30 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Regular fresh cheese (30 g/day for 30 days)
Number of subjects: 30
Study: 21969017

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Standard therapy (control)
Number of subjects: 179
Study: 19358495

Group type: EXPERIMENTAL
Intervention: Routine acupuncture at Dazhui (GV 14), Jingbailao (Ex‐HN 15), and Jianzhongshu (SI 15)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sham acupuncture at 1 cm lateral to Bailao (Ex‐HN 15) and Jianzhongshu (SI 15)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Observation group (acupuncture)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Attack frequency and duration of neck pain
Number of subjects: 106
Study: 16424141

Group type: EXPERIMENTAL
Intervention: BCAA supplementation prior to squat exercise
Number of subjects: 0
Study: 15580123

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 81

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 81
Study: 11167879

Group type: EXPERIMENTAL
Intervention: Packed red cells without buffy coat (PC group)
Number of subjects: 697

Group type: COMPARATOR
Intervention: Filtered, leucoreduced, red cells (LD group)
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Transfused patients
Number of subjects: 697

Group type: COMPARATOR
Intervention: Non-transfused patients
Number of subjects: 697
Study: 10773903

Group type: EXPERIMENTAL
Intervention: Nutrition education
Number of subjects: 40000

Group type: EXPERIMENTAL
Intervention: Mega-dose capsule distribution
Number of subjects: 40000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40000